Ticker

SAN FRANCISCO, CA / ACCESS Newswire / March 4, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC) ("Tivic" or the "Company"), a late-stage immunotherapeutics company, today announced that its Board of Directors has appointed Michael K. Handley as Chief Executive Officer of Tivic, effective immediately.

Initial presentation on January 26, 2026 s howcased Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure. FREMONT, CA / ACCESS Newswire / February 18, 2026 / Tivic (Nasdaq:TIVC), a late-stage immuno-therapeutics company, today announced that a second, follow-up meeting with the Biomedical Advanced Research and Development Authority (BARDA) has…

January 26 Presentation highlighted Entolimod's potential to mitigate and prevent both gastrointestinal and hematopoietic injury from ionizing radiation exposure BARDA has requested a follow-up meeting to continue the discussion on the potential utility of Entolimod as a drug for the Strategic National Stockpile Showcased clinical results, regulatory progression, and manufacturing readiness accelerated by newly…

CEO Presentation to Include Updates and Further Information on the Following Topics: Entolimod Cell Line Verification Success; 200x Manufacturing Scale-Up with Reproducible Quality; BARDA TechWatch Engagement; Creation of Velocity Bioworks, An Integrated CDMO To Accelerate Commercial Readiness FREMONT, CA / ACCESS Newswire / January 26, 2026 / Tivic Health® Systems, Inc. (Nasdaq:TIVC), a late-stage…

Tivic Health Systems, Inc. (NASDAQ: TIVC - Get Free Report) shares rose 0.8% during mid-day trading on Wednesday. The company traded as high as $1.31 and last traded at $1.27. Approximately 67,468 shares traded hands during trading, a decline of 57% from the average daily volume of 158,292 shares. The stock had previously closed at